Zymeworks & Roche Forge $ZW209 Deal, Boosting Shares and Investor Momentum
Zymeworks partners with Roche to develop the promising DLL3‑targeting trispecific T‑cell engager ZW209, boosting investor confidence and potential growth.
3 minutes to read
ZYMEWORKS INC
Zymeworks Shares Rise 4.5% to $28.44, Outperforming Biotech Averages
Zymeworks rises 4.48% to $28.44, trading above its 200‑day MA and 52‑week low—steady gains, strong biotech peer comparison, and a focus on oncology therapeutics.
3 minutes to read
Zymeworks Shares Rise 2% to $26.91, Above 200‑Day SMA, Anticipating Trial Milestones
Explore Zymeworks’ recent 2% gain above its 200‑day SMA— a biotech watchlist stock trading at $26.91, $1.8B cap, with potential upside from upcoming clinical milestones.
2 minutes to read